Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5427]

ECHELON-2: a large peripheral T-cell lymphoma trial

Dr Owen O'Connor - Columbia University Medical Centre, New York, USA

ECHELON-2: a large peripheral T-cell lymphoma trial ( Dr Owen O'Connor - Columbia University Medical Centre, New York, USA )

ACT-1: Addition of alemtuzumab to a CHOP backbone for young patients with T...

Dr Owen O'Connor - Columbia University Medical Centre, New York, USA

ACT-1: Addition of alemtuzumab to a CHOP backbone for young patients with T-cell lymphoma ( Dr Owen O'Connor - Columbia University Medical Centre, New York, USA )

Link between gut microbiota and haematopoietic cell transplantation outcomes

Dr Jonathan Peled - Memorial Sloan Kettering Cancer Centre, New York, USA

Link between gut microbiota and haematopoietic cell transplantation outcomes ( Dr Jonathan Peled - Memorial Sloan Kettering Cancer Centre, New York, USA )

Progression-free survival milestones in primary central nervous system lymphoma

Dr Jorne Lionel Biccler - Aalborg University, Aalborg, Denmark

Progression-free survival milestones in primary central nervous system lymphoma ( Dr Jorne Lionel Biccler - Aalborg University, Aalborg, Denmark )

Relapse risk and loss in expectation of lifetime in young classical hodgkin...

Dr Jorne Lionel Biccler - Aalborg University, Aalborg, Denmark

Relapse risk and loss in expectation of lifetime in young classical hodgkin lymphoma patients ( Dr Jorne Lionel Biccler - Aalborg University, Aalborg, Denmark )

New therapies for transfusion dependent MDS patients

Dr Alan List - Moffitt Cancer Centre, Tampa, USA

New therapies for transfusion dependent MDS patients ( Dr Alan List - Moffitt Cancer Centre, Tampa, USA )

Reduction of chemotherapy cycles for diffuse large B-cell lymphoma

Dr Viola Pöschel - Saarland University Medical School, Homburg, Germany

Reduction of chemotherapy cycles for diffuse large B-cell lymphoma ( Dr Viola Pöschel - Saarland University Medical School, Homburg, Germany )

Inhibiting the immune system’s natural response may boost benefits and...

Dr Shannon Maude - Children’s Hospital of Philadelphia, Philadelphia, USA

Inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy ( Dr Shannon Maude - Children’s Hospital of Philadelphia, Philadelphia, USA )

Ibrutinib alone and in combination with rituximab for older patients with...

Dr Jennifer Woyach - The Ohio State University Comprehensive Cancer Centre...

Ibrutinib alone and in combination with rituximab for older patients with chronic lymphocytic leukaemia ( Dr Jennifer Woyach - The Ohio State University Comprehensive Cancer Centre, Columbus, USA )

Improving toxicity and outcomes by taking ibrutinib during and after CAR T-cell...

Dr Jordan Gauthier - Fred Hutchinson Cancer Research Centre, Seattle, USA

$Improving toxicity and outcomes by taking ibrutinib during and after CAR T-cell therapy for relapsed and/or refractory CLL ( Dr Jordan Gauthier - Fred Hutchinson Cancer Research Centre, Seattle, USA )$

Latest results from JULIET: Tisagenlecleucel in adults with DLBCL

Dr Richard Maziarz - Oregon Health & Science Knight Cancer Institute, Portland...

Latest results from JULIET: Tisagenlecleucel in adults with DLBCL ( Dr Richard Maziarz - Oregon Health & Science Knight Cancer Institute, Portland, USA )

CAR T-Cell therapy with concurrent ibrutinib for chronic lymphocytic leukaemia

Dr Jordan Gauthier - Fred Hutchinson Cancer Research Centre, Seattle, USA

CAR T-Cell therapy with concurrent ibrutinib for chronic lymphocytic leukaemia ( Dr Jordan Gauthier - Fred Hutchinson Cancer Research Centre, Seattle, USA )

More from ecancer